# US 2026/0007769 A1 · Compositions and methods for delivery of rna

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0007769 A1
- Document ID: US20260007769A1
- Status: Published application
- Kind: A1
- Application number: 19/324,932
- Filed: 2025-09-10
- Published: 2026-01-08
- Earliest claimed: 2020-03-23
- Assignees: HDT Bio Corp.
- Applicants: HDT Bio Corp.
- Inventors: Amit Khandhar; Steven Reed; Malcolm Duthie; Jesse Erasmus; Darrick Carter; Bryan J. Berube
- Web page: https://patentgrep.com/patent/US20260007769A1

## CPC

- A61K 39/12: Viral antigens
- A61K 47/6907: {the form being a microemulsion, nanoemulsion or micelle}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/5115: {Inorganic compounds}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/02: Inorganic compounds
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K 47/6911: {the form being a liposome}
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 49/183: {having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus}
- A61K 49/1833: {having a (super)(para)magnetic core coated or functionalised with a small organic molecule (oligomeric, polymeric, dendrimeric A61K49/1851)}
- A61P 31/14: for RNA viruses
- C07K 14/165: Coronaviridae, e.g. avian infectious bronchitis virus
- C07K 16/116: Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
- C12N 15/86: Viral vectors
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/547: {Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- B82Y 25/00: Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
- B82Y 30/00: Nanotechnology for materials or surface science, e.g. nanocomposites
- B82Y 40/00: Manufacture or treatment of nanostructures
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/36143: viral genome or elements thereof as genetic vector
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

## Claims

### Claim 1

A composition, wherein the composition comprises:
nucleic acids, wherein the nucleic acids comprise a sequence encoding for an antigen derived from a cancer; and
lipid nanoparticles, wherein the lipid nanoparticles are characterized as having a z-average diameter particle size measurement of about 20 nm to about 60 nm when measured using dynamic light scattering, and wherein the lipid nanoparticles comprise:
a surface comprising cationic lipids, wherein the cationic lipids comprise from about 0.2% to 10% w/v 1,2-dioleoyloxy-3-(trimethylammonium)propane (DOTAP); and
a hydrophobic core, wherein the hydrophobic core comprises liquid oil, wherein the liquid oil comprises from about 2% to 40% w/v squalene, and wherein lipids present in the hydrophobic core are in liquid phase at 25 degrees Celsius,
wherein the nucleic acids are complexed to the cationic lipids to form nucleic acid-lipid nanoparticle complexes.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition is formulated as a dry powder.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the lipid nanoparticles further comprise a hydrophobic surfactant.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the hydrophobic surfactant comprises sorbitan monostearate, sorbitan monooleate, or sorbitan trioleate.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the lipid nanoparticles further comprise a hydrophilic surfactant.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the hydrophilic surfactant comprises polysorbate 80.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the composition further comprises sodium citrate.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the nucleic acids comprise at least one nucleic acid comprises a sequence encoding for an RNA polymerase complex region.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the RNA polymerase complex region is from an RNA virus.

### Claim 10 (depends on 8)

The composition of claim 8, wherein the RNA polymerase complex region comprises sequence from a Venezuelan equine encephalitis virus

### Claim 11 (depends on 1)

The composition of claim 1, wherein the nucleic acids comprise an RNA, a DNA, or a combination thereof.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the cationic lipids further comprise: 3b-[N—(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DC Cholesterol); dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl-3-trimethylammoniumpropane (DMTAP); dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP); distearoyltrimethylammonium propane (DSTAP); N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA); N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC); 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA); or 1, r-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl) (2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C 12-200).

### Claim 13 (depends on 1)

The composition of claim 1, wherein the lipid nanoparticles are characterized as having a z-average diameter particle size measurement of 40 nm to 60 nm when measured using dynamic light scattering.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the nucleic acid-lipid nanoparticle complexes are characterized as having a z-average diameter particle size measurement of about 90 nm when measured using dynamic light scattering.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the composition further comprises a nucleic acid encoding a protein, a protein, a nucleic acid encoding an antibody, an antibody, or an oncolytic viral RNA.

### Claim 16 (depends on 1)

The composition of claim 1, wherein the composition further comprises an adjuvant for innate immune stimulation.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the adjuvant for innate immune stimulation comprises a toll-like receptor (TLR) agonist or a RIG-I agonist.

### Claim 18 (depends on 1)

The composition of claim 1, wherein the composition comprises:
0.2% to 40% w/v liquid oil;
0.2% to 10% w/v cationic lipid;
0.25% to 5% w/v hydrophobic surfactant; and
0.5% to 10% w/v hydrophilic surfactant.

### Claim 19 (depends on 1)

The composition of claim 1, wherein the composition further comprises sucrose or dextrose.

### Claim 20 (depends on 1)

The composition of claim 1, wherein the composition comprises:
37.5 mg/ml squalene;
37 mg/ml sorbitan monostearate;
37 mg/ml polysorbate 80;
30 mg/ml DOTAP; and
10 mM sodium citrate dihydrate.
